<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00669149</url>
  </required_header>
  <id_info>
    <org_study_id>CHPAU 2007/01</org_study_id>
    <nct_id>NCT00669149</nct_id>
  </id_info>
  <brief_title>Anticoagulant Treatments and Percutaneous Coronary Angioplasty</brief_title>
  <acronym>TACA</acronym>
  <official_title>Anticoagulant Treatments Evaluation During Percutaneous Coronary Angioplasty in Stable Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier de PAU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier de PAU</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether adjunction of intravenous anticoagulant
      therapy (enoxaparin, HNF, bivalirudin) to antiaggregation with clopidogrel and aspirin
      improves in-hospital results of percutaneous transluminal coronary angioplasty (ptca) in
      selected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Background : We don't know if using IV anticoagulant therapy is necessary for
           percutaneous coronary angioplasty in stable patients.

        -  Purpose : to compare efficacy and security of use or not of different anticoagulant
           treatments during percutaneous coronary angioplasty in patients with double
           antiaggregant therapy.

        -  Abstract : In stable patients pretreated with double antiaggregant therapy use of IV
           anticoagulants has not been yet evaluated during angioplasty. In this prospective
           randomized trial we want to compare in such patients the efficacy and security of the
           administration of IV heparin, IV enoxaparin, IV bivalirudin and no use of anticoagulant
           during coronary angioplasty. We will evaluate in each group ischaemic events (clinic,
           ECG and biology) and haemorrhagic events (clinic, biology) with a one month follow up.

        -  Primary outcome: ischaemic events via troponin Ic measurements during 24 hours post
           procedure.

        -  Secondary outcomes: haemorrhagic events : clinical and biological evaluation (Hb, Ht,
           TIMI score)

        -  Study design : monocentric randomized clinical trial type therapeutic equivalence phase
           IV.

        -  Interventions : In patients prepared with therapeutic association (aspirin clopidogrel)
           comparison between use or no of anticoagulant (IV heparin, IV enoxaparin or IV
           bivalirudin).

        -  Number of subjects : 120 per group (total of 480).

        -  Statistical analysis : multivariate analysis with logistic regression models : each end
           point (troponin Ic increase, haemoglobin decrease, …) will be explicated with treatment
           group and other covariates (sex, age, creatinine, …).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ischaemic events via troponin Ic measurements during 24 hours post procedure</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>haemorrhagic events : clinical and biological evaluation</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>group without anticoagulant therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with enoxaparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>group with bivalirudin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel + aspirin</intervention_name>
    <arm_group_label>1</arm_group_label>
    <other_name>Plavix Kardégic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>heparin + clopidogrel + aspirin</intervention_name>
    <arm_group_label>2</arm_group_label>
    <other_name>héparine Choay Plavix Kardégic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>enoxaparin + clopidogrel + aspirin</intervention_name>
    <arm_group_label>3</arm_group_label>
    <other_name>Lovenox Plavix Kardégic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bivalirudin + clopidogrel + aspirin</intervention_name>
    <arm_group_label>4</arm_group_label>
    <other_name>Angiox Plavix Kardégic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable angina pectoris or silent ischaemia

        Exclusion Criteria:

          -  instable angina or ACS (Acute Coronary Syndrome)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas DELARCHE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH de Pau</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas DELARCHE, MD</last_name>
    <phone>55-992-4883</phone>
    <phone_ext>33</phone_ext>
    <email>n.delarche@wanadoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Pau</name>
      <address>
        <city>PAU</city>
        <state>Pyrénées-Atlantiques</state>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane DEBEUGNY, MD</last_name>
      <phone>55-972-6801</phone>
      <phone_ext>33</phone_ext>
      <email>stephane.debeugny@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Nicolas DELARCHE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raphaël LASSERRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2008</study_first_submitted>
  <study_first_submitted_qc>April 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2008</study_first_posted>
  <last_update_submitted>July 1, 2011</last_update_submitted>
  <last_update_submitted_qc>July 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2011</last_update_posted>
  <responsible_party>
    <name_title>Stéphane DEBEUGNY, MD</name_title>
    <organization>Centre Hospitalier de PAU</organization>
  </responsible_party>
  <keyword>ptca</keyword>
  <keyword>antiaggregant therapy</keyword>
  <keyword>anticoagulant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

